Vicapsys Life Sciences (PK) Stock Price - VICP

2.50
0.00 (0.0%)
2.50
Best deals to access real time data!
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
Small Cap Pro
Monthly Subscription
for only
$49.05
Canna Trader Pro
Monthly Subscription
for only
$59.99
VAT not included
Company Name Stock Ticker Symbol Market Type
Vicapsys Life Sciences Inc (PK) VICP OTCMarkets Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.00 0.0% 2.50 0.00 0.00 0.00 2.50 07:19:44
Bid Price Ask Price Spread Spread % News
1.50 2.50 1.00 40.0% - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 2.50 USD

Vicapsys Life Sciences (PK) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 43.71M 17.48M - $ - $ - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Vicapsys Life Sciences (PK) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical VICP Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.0%
1 Month2.502.502.502.501000.000.0%
3 Months2.502.502.502.501000.000.0%
6 Months1.502.501.502.362331.0066.67%
1 Year2.402.601.502.432190.104.17%
3 Years4.004.711.502.93138-1.50-37.5%
5 Years4.004.711.502.93138-1.50-37.5%

Vicapsys Life Sciences (PK) Description

ViCapsys, based in Athens, GA, is a development stage biotechnology company that is advancing a proprietary localized immune modulator. ViCapsys’s technology allows physicians to control the body’s immune system in regional areas around an implant, which reduces the risk of transplant rejection or fibrotic overgrowth due to foreign body recognition. The product offers wide ranging benefits in multiple surgical applications including, organ transplants, medical device implantations, and wound healing, without the need for systemic immune suppression. ViCapsys is currently investigating three initial pipeline products treating type 1 diabetes, post-surgical abdominal adhesion formation, and post-trauma keloid formation. The company intends to develop and license other technologies related to immune modulation going forward.


Your Recent History
USOTC
VICP
Vicapsys L..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.